Oxford Asset Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Oxford Asset Management’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$22K	Sell	1,381 -55,966	-98%	-$1.19M	﹤0.01%	182
2019 Q4	$1.23M	Buy	57,347 +2,258	+4%	+$46.5K	0.03%	737
2019 Q3	$1.03M	Buy	55,089 +35,336	+179%	+$730K	0.02%	931
2019 Q2	$516K	Buy	+19,753	New	+$446K	0.01%	1268
2017 Q1	–	Sell	-1,379	Closed	-$33K	–	1464
2016 Q4	$33K	Sell	1,379 -13,952	-91%	-$400K	﹤0.01%	750
2016 Q3	$563K	Buy	+15,331	New	+$439K	0.02%	606
2015 Q4	–	Sell	-10,480	Closed	-$259K	–	931
2015 Q3	$259K	Sell	10,480 -20,898	-67%	-$624K	0.01%	561
2015 Q2	$1.01M	Sell	31,378 -33,926	-52%	-$1.3M	0.03%	445
2015 Q1	$2.33M	Buy	65,304 +46,737	+252%	+$1.28M	0.06%	332
2014 Q4	$426K	Buy	+18,567	New	+$376K	0.01%	576
2014 Q2	–	Sell	-5,616	Closed	-$218K	–	760
2014 Q1	$218K	Buy	+5,616	New	+$200K	0.01%	587

Other funds holding RIGL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Oxford Asset Management's RIGL Position: Q1 2020 in Review

Oxford Asset Management reduced its Rigel Pharmaceuticals (RIGL) stake by 98% in Q1 2020, selling an estimated $1.19M and leaving 1,381 shares worth $22K. The position accounts for ﹤0.01% of the portfolio, ranked #182.

Oxford Asset Management first reported a position in RIGL in Q1 2014 and has held it in 11 quarters since. The position peaked at $2.33M in Q1 2015. 126 funds tracked by Wall St. Rank hold RIGL as of Q1 2020.

Oxford Asset Management held 1,381 shares of Rigel Pharmaceuticals worth $22K as of Q1 2020.
Oxford Asset Management sold 55,966 Rigel Pharmaceuticals shares in Q1 2020, an estimated $1.19M.
Rigel Pharmaceuticals made up ﹤0.01% of Oxford Asset Management's portfolio in Q1 2020, its #182 holding.
Oxford Asset Management first reported a position in Rigel Pharmaceuticals in Q1 2014 and has held it in 11 quarters since.
Oxford Asset Management's Rigel Pharmaceuticals position peaked at $2.33M in Q1 2015.
126 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.